About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Nuclear Medicine Communications
›
top-articles
Nuclear Medicine Communications
1.3
(top 50%)
impact factor
10.5K
(top 2%)
papers
78.4K
(top 5%)
citations
88
(top 5%)
h
-index
1.3
(top 50%)
extended IF
11.6K
all documents
81.3K
doc citations
116
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
PET versus SPECT: strengths, limitations and challenges
Nuclear Medicine Communications
2008
662
2
99Tcm sestamibi — a new agent for parathyroid imaging
Nuclear Medicine Communications
1989
419
3
Guidelines for the measurement of glomerular filtration rate using plasma sampling
Nuclear Medicine Communications
2004
267
4
A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG)
Nuclear Medicine Communications
1992
255
5
111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction
Nuclear Medicine Communications
2003
202
6
FDG uptake, tumour characteristics and response to therapy
Nuclear Medicine Communications
1998
177
7
Subtraction ictal SPET co-registered to MRI in partial epilepsy
Nuclear Medicine Communications
1998
174
8
Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy
Nuclear Medicine Communications
2001
173
9
Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology
Nuclear Medicine Communications
2007
168
10
FDG PET in the diagnosis of hilar cholangiocarcinoma
Nuclear Medicine Communications
2001
153
11
Nuclear medicine imaging of bone infections
Nuclear Medicine Communications
2006
151
12
Review of functional/anatomical imaging in oncology
Nuclear Medicine Communications
2012
148
13
Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer
Nuclear Medicine Communications
2014
146
14
The importance of the location of fluorodeoxyglucose uptake in periprosthetic infection in painful hip prostheses
Nuclear Medicine Communications
2002
144
15
Whole-body 18F-FDG PET for the evaluation of patients with Hodgkinʼs disease and non-Hodgkinʼs lymphoma
Nuclear Medicine Communications
1999
142
16
Determination of the prognostic value of [18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer
Nuclear Medicine Communications
2002
141
17
Potential role of FDG PET in the setting of diabetic neuro-osteoarthropathy: can it differentiate uncomplicated Charcot's neuroarthropathy from osteomyelitis and soft-tissue infection?
Nuclear Medicine Communications
2007
138
18
Repeatability and reproducibility of phase analysis of gated single-photon emission computed tomography myocardial perfusion imaging used to quantify cardiac dyssynchrony
Nuclear Medicine Communications
2008
137
19
Technegas - a new ventilation agent for lung scanning
Nuclear Medicine Communications
1986
136
20
Value of FDG PET in patients with fever of unknown origin
Nuclear Medicine Communications
2001
136
21
Clinical outcome of radiosynoviorthesis: a meta-analysis including 2190 treated joints
Nuclear Medicine Communications
2002
136
22
Is SPECT/CT with a hybrid camera useful to improve scintigraphic imaging interpretation?
Nuclear Medicine Communications
2004
136
23
Diagnosis of chronic thromboembolic pulmonary hypertension
Nuclear Medicine Communications
2012
136
24
Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma
Nuclear Medicine Communications
1998
134
25
Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG)
Nuclear Medicine Communications
2001
133
26
Unexpected 99mTc-tetrofosmin findings during myocardial perfusion scintigraphy: intraindividual comparison with PET/computed tomography
Nuclear Medicine Communications
2008
133
27
18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer
Nuclear Medicine Communications
2010
129
28
Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging
Nuclear Medicine Communications
2016
126
29
Is a lung perfusion scan obtained by using single photon emission computed tomography able to improve the radionuclide diagnosis of pulmonary embolism?
Nuclear Medicine Communications
2002
125
30
Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67
Nuclear Medicine Communications
2002
125
31
Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging
Nuclear Medicine Communications
2015
125
32
Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma
Nuclear Medicine Communications
2014
124
33
The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective
Nuclear Medicine Communications
2004
123
34
Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours
Nuclear Medicine Communications
2006
123
35
Parathyroid adenoma localization with 99mTc-sestamibi SPECT/CT
Nuclear Medicine Communications
2015
123
36
Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme
Nuclear Medicine Communications
2001
121
37
Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis
Nuclear Medicine Communications
2009
120
38
FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation
Nuclear Medicine Communications
2001
119
39
Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography
Nuclear Medicine Communications
2009
119
40
Development of a 99Tcm-labelled radiopharmaceutical for cerebral blood flow imaging
Nuclear Medicine Communications
1985
118
41
Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET
Nuclear Medicine Communications
2004
118
42
SPECT neuropsychological activation procedure with the Verbal Fluency Test in attempted suicide patients
Nuclear Medicine Communications
2002
116
43
Conversion of brain SPECT images between different collimators and reconstruction processes for analysis using statistical parametric mapping
Nuclear Medicine Communications
2004
115
44
Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging
Nuclear Medicine Communications
2009
115
45
A 99Tcm-labelled radiotracer for the investigation of cerebral vascular disease
Nuclear Medicine Communications
1985
110
46
A technique for using CT images in attenuation correction and quantification in SPECT
Nuclear Medicine Communications
1989
110
47
Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience
Nuclear Medicine Communications
2004
110
48
Applications of fluorodeoxyglucose positron emission tomography in the diagnosis of infection
Nuclear Medicine Communications
2003
109
49
Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma
Nuclear Medicine Communications
2004
109
50
Whole-body PET/CT: Spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients
Nuclear Medicine Communications
2005
109
site/software ©
exaly
; All materials licenced under
CC by-SA
.